Related Experiment Video
Updated: Jan 19, 2026

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial
Pascal Vranckx1, Sergio Leonardi2, Matteo Tebaldi3
1Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium Department of Cardiology, Thoraxcentre, Erasmus Medical Center, Rotterdam, The Netherlands Thoraxcentre, Erasmus Medical Center, Rotterdam, The Netherlands.
Insights
The Bleeding Academic Research Consortium (BARC) classification identifies bleeding events in cardiovascular trials. BARC Type 3 or 5 bleedings predict mortality similarly to TIMI and GUSTO scales.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials Methodology
- Hemorrhagic Event Classification
Background:
- Standardized bleeding definitions are crucial for cardiovascular clinical trials.
- The Bleeding Academic Research Consortium (BARC) classification was developed by consensus for this purpose.
- The prognostic impact of BARC-defined bleeding in prospective studies remains largely unexamined.
Purpose of the Study:
- To assess the prognostic value of BARC-defined bleeding in predicting mortality.
- To compare the predictive performance of BARC criteria against established bleeding scales (TIMI and GUSTO).
- To analyze bleeding events and mortality in a contemporary, all-comer percutaneous coronary intervention trial.
Main Methods:
- Prospective adjudication of non-coronary artery bypass graft (CABG)-related bleeding events by a blinded Clinical Event Committee within the PRODIGY trial.
- Analysis of bleeding occurrences (BARC Type 2, 3, or 5; TIMI minor/major; GUSTO moderate/severe) and 2-year mortality.
- Multivariable statistical modeling to determine the association between bleeding types and mortality risk.
Main Results:
- At 2 years, 7.1% of patients experienced BARC Type 2, 3, or 5 bleeding, 2.5% had TIMI minor/major bleeding, and 3.1% had GUSTO moderate/severe bleeding.
- BARC Type 2, 3, or 5 bleeding was significantly associated with increased 2-year mortality (HR: 3.77).
- BARC Type 3 or 5 bleeding demonstrated a similar mortality risk prediction as TIMI and GUSTO criteria (adjusted HRs ranging from 7.36 to 7.72).
Conclusions:
- Actionable BARC bleedings are associated with an elevated risk of mortality in patients undergoing percutaneous coronary intervention.
- BARC Type 3 or 5 bleeding classifications offer prognostic value comparable to TIMI and GUSTO scales.
- These findings support the utility of BARC criteria for risk stratification in cardiovascular trials.
Aims:
The Bleeding Academic Research Consortium (BARC) classification has been proposed by consensus to standardize bleeding endpoint definition and reporting in cardiovascular clinical trials. There are no prospective studies on its prognostic impact.
Methods And Results:
We explored the association of BARC-defined bleeding with mortality and compared its prognostic value against two validated bleeding scales: the Thrombolysis in Myocardial Infarction (TIMI) and the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) scales. Non-coronary artery bypass graft (CABG)-related bleedings within the PRODIGY trial were prospectively adjudicated by a blinded Clinical Event Committee and analysed according to multiple statistical modelling. At 2 years, bleeding occurred in 143 patients (7.1%) according to BARC Type 2, 3, or 5; in 50 patients (2.5%) according to TIMI minor or major; and in 61 patients (3.1%) according to GUSTO moderate or severe. One hundred sixty-three patients died (8.1%). After multivariable modelling, BARC Type 2, 3, or 5 bleeding was associated with increased 2-year mortality [hazard ratio (HR): 3.77; 95% confidence interval (CI): 2.37-5.98]. Bleeding Academic Research Consortium Type 3 or 5 was associated with an increased mortality rate at 2 years (adjusted HR: 7.72; 95% CI: 4.75-12.54) similar to that provided by TIMI (HR: 7.64, 95% CI: 4.53-12.87) or GUSTO (HR: 7.36, 95% CI: 4.38-12.34) criteria.
Conclusions:
In a contemporary, all-comer percutaneous coronary intervention trial actionable BARC bleedings were associated with increased risk of mortality with BARC Type 3 or 5 bleedings providing a similar mortality risk to that posed by TIMI or GUSTO scales.
Related Concept Videos
03:26Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain
Prospect Theory
09:49Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation
Bleeding in Fresh Concrete
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
Reliability and Validity
Clinical Trials
There are four phases in a clinical trial. A phase one...
